phrykt

Cellectar Biosciences, Inc. (CLRB): who owns it and who trades it

As of Nov 16, 2026, CLRB insiders reported 1 open-market sale worth $733 and 1 purchase worth $25K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was John Neis (Director), with $733.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, CLRB insiders reported $25K of open-market purchases and $733 of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$25K
1 trades, 1 people
Sales, 12 months
$733
1 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
May 7, 2026
Filed May 11, 2026

Purchases and sales by month

$25K$25KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
May 7, 2026Jarrod LongcorChief Operating OfficerPurchase8,680$2.88$25KForm 4
Dec 12, 2025John NeisDirectorSale198$3.70$733Form 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jarrod LongcorChief Operating Officer$25K–May 7, 2026
John NeisDirector–$733Dec 12, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CLRB short interest

Low short interest. 2.3% of CLRB shares are sold short: about 1 share in 43. Over the last 12 reports the number of shares short went down 72%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 218,774 CLRB shares were sold short, 2.3% of the shares outstanding, down 17.0% from the report before. At the average daily volume of 132,705 shares, buying them all back would take about 1.6 trading days (days to cover).

Shares short, % of all shares

2.31%May 15Oct 3020.9%

Days to cover

1.6May 15Oct 306.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026218,7742.31%-17%132,7051.6
Oct 15, 2026263,5172.79%+58%194,3811.4
Sep 30, 2026166,2651.76%-13%81,2882.0
Sep 15, 2026191,1282.02%+14%41,7814.6
Aug 31, 2026166,9851.77%+4%27,3026.1
Aug 14, 2026161,1971.71%-8%29,8955.4
Jul 31, 2026174,8294.12%-12%44,4673.9
Jul 15, 2026199,4364.70%+3%118,5711.7
Jun 30, 2026194,3364.58%+239%156,9631.2
Jun 15, 202657,3561.35%-78%153,0601.0
May 29, 2026258,2026.09%-67%236,0601.1
May 15, 2026777,62218.34%+3288%5.14M1.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Cellectar Biosciences company events

Cellectar Biosciences filed 7 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Aug 13, 2026ResultsReleased financial results. Filing
  3. Jul 10, 2026LeadershipAs described in Item 5.07 below, on July 7, 2026, at the 2026 Annual Meeting of Stockholders of Cellectar Biosciences, Inc., the Company’s stockholders approved an amendment to the Company’s 2021 Stock Incentive Plan to increase the number of shares reserved for issuance under the Plan by 2,000,000… Filing
  4. May 18, 2026LeadershipStefan D. Loren, Ph.D. notified the board of directors of Cellectar Biosciences, Inc., that he does not intend to stand for reelection as a Class III director at the upcoming 2026 annual meeting of the stockholders of the Company, at which time his current term as a director will expire. Filing
  5. May 14, 2026ResultsReleased financial results. Filing
  6. May 8, 2026AgreementCellectar Biosciences, Inc., a Delaware corporation entered into a securities purchase agreement with certain institutional investors, to issue and sell in a registered direct offering 1,618,053 shares of the Company’s common stock, $0.00001 par value per share The Registered Offering was made… Filing
  7. Mar 4, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Cellectar Biosciences financials

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named CLRB in the last 120 days.

FiledHolderFormStake
Nov 16, 2026BALYASNY ASSET MANAGEMENT L.P.13G/A10.0%
Nov 16, 2026BALYASNY ASSET MANAGEMENT L.P.13G/A10.0%

Questions about Cellectar Biosciences, Inc. (CLRB) stock

Are CLRB insiders buying or selling?

In the last 12 months, CLRB insiders reported 1 open-market purchase worth $25K and 1 sale worth $733. The latest trade was on May 7, 2026. See every trade.

What is the short interest in CLRB?

As of Oct 30, 2026, 218,774 CLRB shares were sold short, 2.3% of the shares outstanding, down 17.0% from the report before. At the average daily volume of 132,705 shares, buying them all back would take about 1.6 trading days (days to cover). See the history.

Executive pay

Cellectar Biosciences's chief executive was paid a total of $1.1M for the year ended Dec 31, 2025, down 65% from $3M the year before. In the last 12 months, Cellectar Biosciences's executives and directors bought $25K of stock on the open market and sold $733.

Chief executive, total pay$1.1MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$887KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$694KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.